var data={"title":"Antimalarial drugs: An overview","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Antimalarial drugs: An overview</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/contributors\" class=\"contributor contributor_credentials\">Mark Travassos, MD, MSc</a></dd><dd><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/contributors\" class=\"contributor contributor_credentials\">Miriam K Laufer, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/contributors\" class=\"contributor contributor_credentials\">Johanna Daily, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 09, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 1</a>). The extent of preerythrocytic (hepatic stage) activity for most antimalarial drugs is not well characterized.</p><p>Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. In addition, for infection due to <em>Plasmodium ovale</em> or <em>Plasmodium vivax</em>, terminal prophylaxis is required with a drug active against hypnozoites (which can remain dormant in the liver for months and, occasionally, years after the initial infection).</p><p>The mechanisms of action, resistance, and toxicities of antimalarial drugs will be reviewed here. Use of these agents for prevention and treatment of malaria is discussed in detail separately. (See <a href=\"topic.htm?path=prevention-of-malaria-infection-in-travelers\" class=\"medical medical_review\">&quot;Prevention of malaria infection in travelers&quot;</a> and <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a> and <a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Treatment of uncomplicated falciparum malaria in nonpregnant adults and children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">QUINOLINE DERIVATIVES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Quinoline derivatives include <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, amodiaquine, <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a>, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a>, lumefantrine, and halofantrine. These drugs have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 1</a>). The drugs act by accumulating in the parasite food vacuole and forming a complex with heme that prevents crystallization in the <em>Plasmodium </em>food vacuole. Heme polymerase activity is inhibited, resulting in accumulation of cytotoxic-free heme.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">4-aminoquinolines</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Chloroquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> was the first drug produced on a large scale for treatment and prevention of malaria infection. Chloroquine has activity against the blood stages of <em>P. ovale</em>, <em>P. malariae</em>, and susceptible strains of <em>P. vivax</em> and <em>P. falciparum </em>[<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/1\" class=\"abstract_t\">1</a>]. Widespread resistance in most malaria-endemic countries has led to decline in its use for the treatment of <em>P. falciparum</em>, although it remains effective for treatment of <em>P. ovale</em>, <em>P. malariae</em>, and, in most regions, <em>P. vivax</em>. (See <a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">&quot;Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae&quot;</a>.)</p><p><a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> penetrates into most tissues and therefore has a large volume of distribution. As a result, serum drug levels may be maintained for up to two months [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/2\" class=\"abstract_t\">2</a>]. Side effects of chloroquine include headaches, dizziness, abdominal discomfort, vomiting, and diarrhea. Chloroquine may also produce pruritus in some patients; this has been noted to occur most frequently in African populations [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/3\" class=\"abstract_t\">3</a>]. The pruritus is transient, lasting 48 to 72 hours, and is not responsive to antihistamines.</p><p>Severe adverse reactions are extremely rare. Some are associated only with prolonged use, such as neuromyopathy with long-term prophylaxis and retinopathy with high-dose administration for treatment of rheumatologic diseases (total doses of 1 <span class=\"nowrap\">g/kg</span> or prophylaxis for greater than one year). Rare cases of idiosyncratic reactions, such as erythema multiforme and bone marrow toxicity, have been reported [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/4\" class=\"abstract_t\">4</a>]. <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">Chloroquine</a> is only administered orally; intravenous infusion is associated with significant toxicity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p>Among chloroquine-resistant parasites, there is decreased accumulation of drug within the food vacuole. Mutations in the gene encoding the chloroquine-resistance transporter protein (PfCRT), located in the food vacuole, are associated with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> resistance both in vitro and in vivo [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Tracing the spread of this gene mutation has led to the current understanding that chloroquine resistance developed independently in Asia, Papua New Guinea, and South America. The chloroquine-resistant gene that emerged in Southeast Asia spread across the Asian continent and reached Africa in the late 1970s [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Mutations in the homolog of the major multidrug-transporter <em>P. falciparum</em> multidrug-resistance protein-1 (<em>pfmdr1</em>) may modulate the extent of chloroquine resistance as well as resistance to other antimalarials [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Amodiaquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amodiaquine is similar in structure to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, and there is cross-resistance between the two drugs, although amodiaquine retains some activity against chloroquine-resistant parasites in vivo and in vitro [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/12-14\" class=\"abstract_t\">12-14</a>].</p><p>Amodiaquine is commonly used in malaria-endemic countries as one of the few drugs available to treat chloroquine-resistant infections and is available in coformulation with <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/15\" class=\"abstract_t\">15</a>]. Amodiaquine is well tolerated when administered as a single course of treatment over three days. Trials evaluating a three-day treatment course of amodiaquine for uncomplicated malaria noted mild to moderate adverse effects (including nausea, emesis, and pruritus), with no significant hepatotoxicity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/13,16\" class=\"abstract_t\">13,16</a>]. Adverse event rates were the same as other commonly used antimalarial drugs [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/16,17\" class=\"abstract_t\">16,17</a>]. Declines in neutrophil counts below <span class=\"nowrap\">1000/mm<sup>3</sup></span> have been noted with amodiaquine used for therapy of malaria infection, although the clinical significance is not certain [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/18\" class=\"abstract_t\">18</a>]. Such neutropenia has not been observed with artesunate-amodiaquine treatment [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Amodiaquine has been taken off the market in the United States due to the risk of toxicity associated with prolonged administration for prophylaxis. The most serious adverse effects of amodiaquine are agranulocytosis and hepatotoxicity, which have been reported in European travelers using amodiaquine to prevent malaria. Based on prescription data from the United Kingdom, the frequency of neutropenia with amodiaquine prophylaxis was 1:2200, while that of hepatic toxicity was 1:15,650 [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/20\" class=\"abstract_t\">20</a>]. Case reports have linked such adverse events with total doses of amodiaquine in excess of 1.5 g or with administration over at least one month [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/21,22\" class=\"abstract_t\">21,22</a>].</p><p class=\"headingAnchor\" id=\"H1659878822\"><span class=\"h3\">Piperaquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Piperaquine is a bisquinoline that is closely related to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> and amodiaquine. Piperaquine is used in combination with dihydroartemisinin as combination therapy for treatment of malaria; previously, it was used in China and Southeast Asia for the treatment and prevention of malaria during the second half of the 20<sup>th</sup> century. Piperaquine is effective against chloroquine-resistant parasites [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/23\" class=\"abstract_t\">23</a>]. The half-life is two to three weeks, which is longer than other drugs that are combined with artemisinin derivatives in artemisinin-based combination therapy; therefore, it provides an extended period of post-treatment prophylaxis [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Some studies suggest piperaquine can cause a prolonged QT interval in the absence of clinical symptoms [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/26,27\" class=\"abstract_t\">26,27</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">4-methanolquinolines</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Quinine and quinidine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">Quinine</a> is a derivative from the bark of the South American Cinchona tree and exists in oral and parenteral forms. It is a commonly used parenteral antimalarial drug in malaria-endemic regions. <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">Quinidine</a> is a stereoisomer of quinine available in parenteral formulation and is effective for treatment of severe malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/28\" class=\"abstract_t\">28</a>].</p><p>The adverse effects of <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> and <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a> include a complex of symptoms referred to as cinchonism: tinnitus, nausea, headaches, dizziness, and disturbed vision. These effects are observed to some extent in all patients receiving treatment and typically resolve with cessation of the medication. These symptoms do not warrant change in drug dose. However, toxicity often interferes with compliance in completing the course of therapy. Less commonly, hypersensitivity reaction with bronchospasm and cutaneous manifestations, such as flushing and urticaria, may occur.</p><p><a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">Quinine</a> has a short half-life. When given orally, it must be administered three times per day; when administered together with one week of <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> antibiotics or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, the duration of therapy is three to seven days. The drug should be given for seven days if the infection is acquired in an area where decreased quinine susceptibility has been reported, such as Southeast Asia [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/29\" class=\"abstract_t\">29</a>].</p><p>For severe disease, <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> can be administered intravenously or intramuscularly. Intravenous administration of <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a> and quinine should be as an infusion because rapid boluses are associated with hypotension. To hasten parasite clearance time, an initial loading dose of parenteral quinine or quinidine is appropriate if the patient has not received treatment with these agents recently [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/30\" class=\"abstract_t\">30</a>]. After initial improvement on parenteral therapy, patients can be switched to oral medication. While therapeutic approaches can include completing a course of oral quinine plus an antibiotic (eg, <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>), it may be preferable to give a full course of another oral antimalarial with better tolerability than quinine. (See <a href=\"#H15\" class=\"local\">'Antimicrobials'</a> below and <a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">&quot;Treatment of severe malaria&quot;</a>.)</p><p><a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">Quinine</a> and <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a> have a narrow therapeutic window; overdosage may lead to cardiotoxicity, including arrhythmias and hypotension, blindness, or deafness. Quinidine is the most cardiotoxic of these agents: cardiac monitoring including serial blood pressure measurements should always be in place when quinidine is administered to monitor for prolongation of the QT interval and ventricular tachycardia. Blood sugar levels should be monitored with intravenous infusion, as both quinine and quinidine stimulate insulin production [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/31\" class=\"abstract_t\">31</a>].</p><p>Reduced <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> efficacy has been described in Southeast Asia [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/29\" class=\"abstract_t\">29</a>]. The mechanism for quinine resistance is complex and poorly understood [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/32\" class=\"abstract_t\">32</a>]. The combination of quinine with an antibiotic (<a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>) remains effective in areas where decreased quinine susceptibility has been observed.</p><p>Because <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a> is no longer used routinely as an antiarrhythmic medication in the United States, it may not be readily available; in such circumstances, the manufacturer Eli Lilly may be contacted directly to arrange shipment (telephone 1-800-821-0538).</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Mefloquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a> is available as an oral formulation and may be used as treatment or prophylaxis for all susceptible malaria species.</p><p>Adverse effects of <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> include vomiting and dizziness. Like the other drugs in this class, mefloquine can also interfere with cardiac conduction and therefore should not be used in individuals with cardiac conduction abnormalities.</p><p><a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a> is contraindicated for individuals with neurologic and psychiatric disorders; those with significant family history of seizures and major psychiatric disorders should also avoid taking mefloquine. Seizures, encephalopathy, and psychosis occur in 0.1 to 5 percent of patients treated for malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/33\" class=\"abstract_t\">33</a>]. The extent to which mefloquine is associated with serious neuropsychiatric side effects in the setting of weekly prophylaxis is an area of controversy. The risk of psychosis and panic attacks with mefloquine compared with other antimalarials is increased twofold, although the absolute risk is low (1 to 3 episodes per 1000 person-years of exposure) [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/34,35\" class=\"abstract_t\">34,35</a>]. There is no evidence of an increased risk of depression compared with other antimalarials. Mefloquine users may experience sleep disturbances, including strange dreams and insomnia [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/34\" class=\"abstract_t\">34</a>].</p><p>Mefloquine-induced pneumonitis is an infrequently reported but serious adverse event in the setting of both prophylactic and therapeutic use [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/36-40\" class=\"abstract_t\">36-40</a>]. One-third of the patients improved following treatment with corticosteroids, and most patients fully recovered upon discontinuation of the drug.</p><p>Splitting the 25 <span class=\"nowrap\">mg/kg</span> dose into 15 <span class=\"nowrap\">mg/kg</span> and 10 <span class=\"nowrap\">mg/kg</span> over a 6- to 24-hour period may be helpful to reduce mild adverse effects. When used for prophylaxis, it is best started two to three weeks prior to departure to assess tolerability, though side effects can develop long into the prophylactic course or even if it has been well tolerated in the past.</p><p><a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a> resistance is found primarily in areas of Southeast Asia. Mefloquine treatment failure is associated with an increase in copy number of <em>pfmdr1</em>, which encodes a protein on the digestive vacuole membrane that appears to play a role in regulating traffic across the membrane [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/41\" class=\"abstract_t\">41</a>]. Resistance to the combination of mefloquine plus <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> appears to have emerged in some regions of Southeast Asia [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/42\" class=\"abstract_t\">42</a>]. However, mefloquine-susceptible infections may be more common in that region after the introduction of dihydroartemisinin-piperaquine, an artemisinin-based combination therapy for the treatment of malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/43\" class=\"abstract_t\">43</a>]. (See <a href=\"#H16\" class=\"local\">'Artemisinin derivatives'</a> below.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">8-aminoquinolines</span></p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Primaquine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> is the only 8-aminoquinoline in clinical use; its mechanism of action is not known. It is most commonly used to prevent relapse of <em>P. vivax </em>and <em>P. ovale </em>malaria by eliminating dormant hypnozoites. Primaquine also has activity against the preerythrocytic stage and gametocytes of <em>P. falciparum</em> [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/44\" class=\"abstract_t\">44</a>].</p><p><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> can cause hemolytic anemia in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Therefore, patients should receive primaquine only if G6PD deficiency has been excluded. In addition, electrocardiogram monitoring is warranted when using primaquine in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncorrected hypokalemia <span class=\"nowrap\">and/or</span> hypomagnesemia, or bradycardia (&lt;50 beats per minute) and during concomitant administration with QT interval-prolonging agents [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/45\" class=\"abstract_t\">45</a>]. Primaquine may also cause gastrointestinal upset that can be minimized if taken with food. Primaquine is contraindicated in pregnancy and breastfeeding, even in the setting of a normal maternal G6PD level.</p><p>Hypnozoite resistance to <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> is difficult to assess. Parasitemia within the first four to six weeks of an initial infection may be due to failure of the blood stage treatment, inadequate adherence, or primaquine failure.</p><p>As part of a malaria elimination campaign, the World Health Organization suggests consideration of a single dose of <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a> following an artemisinin-based combination therapy (ACT) regimen to reduce gametocyte carriage [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/46\" class=\"abstract_t\">46</a>]. A single low dose is believed to be safe even in individuals with G6PD deficiency. While ACTs have some activity against gametocytes, the addition of primaquine may further shorten an individual's period of infectivity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/47,48\" class=\"abstract_t\">47,48</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">ANTIFOLATES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifolates include sulfonamides, <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>, proguanil, and <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>. These drugs act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/49\" class=\"abstract_t\">49</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Sulfadoxine-pyrimethamine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sulfadoxine and <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a> target enzymes involved in folate synthesis; pyrimethamine targets dihydrofolate reductase (DHFR), and sulfadoxine acts on dihydropteroate synthase (DHPS). Sulfadoxine-pyrimethamine is available in a fixed-dose tablet; because the components act on enzymes in the same pathway, it is not considered a combination therapy.</p><p>Mild adverse effects include gastrointestinal upset and headache. Mild bone marrow suppression may occur, and sulfadoxine can precipitate hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Severe cutaneous toxicity due to the sulfa moiety can occur, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrosis [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/50,51\" class=\"abstract_t\">50,51</a>].</p><p>Resistance to sulfadoxine-pyrimethamine occurs via mutations in the target enzymes DHFR and DHPS. <em>P. falciparum</em> resistance to sulfadoxine-pyrimethamine is widespread in most malaria-endemic regions. The use of sulfadoxine-pyrimethamine is usually restricted to the prevention of malaria in pregnant women in malaria-endemic countries. Due to high levels of resistance, especially in eastern and southern Africa, uncertainty regarding its effectiveness has been raised [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/52\" class=\"abstract_t\">52</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Atovaquone-proguanil</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a> interferes with two separate pathways involved in the biosynthesis of pyrimidines, which are essential for nucleic acid replication. <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> blocks the parasite mitochondrial electron transport chain, and proguanil inhibits parasite dihydrofolate reductase through its active metabolite, cycloguanil. Proguanil also appears to act via a direct mechanism outside the folate pathway, enhancing atovaquone's mitochondrial membrane toxicity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/53,54\" class=\"abstract_t\">53,54</a>].</p><p>Adverse effects include abdominal pain, vomiting, diarrhea, headache, and pruritus. Among adults in Thailand, mild asymptomatic increases in transaminases were observed shortly after initiating therapy, although they normalized within two weeks [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/55,56\" class=\"abstract_t\">55,56</a>].</p><p>Resistance to <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a> is mediated by mutations in the cytochrome b gene. The polymorphism associated with resistance has been found in parasite populations even in the absence of drug pressure and can arise rapidly when the drug is used [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/57,58\" class=\"abstract_t\">57,58</a>]. However, initial studies suggest that atovaquone-resistant parasites cannot be transmitted through the mosquito [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/59\" class=\"abstract_t\">59</a>]. The combination retains excellent clinical efficacy for treatment and prevention throughout the world even in the presence of antifolate resistance [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/60,61\" class=\"abstract_t\">60,61</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">ANTIMICROBIALS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a>, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, and <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> target prokaryotic protein synthesis. In malaria parasites, these drugs appear to target the apicoplast, an organelle derived from prokaryotic ancestors [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/49\" class=\"abstract_t\">49</a>]. Antimicrobials have relatively slow antimalarial activity because they exert their toxic effects in the subsequent cycle of cell division [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/49,62\" class=\"abstract_t\">49,62</a>]. They are typically paired with fast-acting antimalarials (usually <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a>). Doxycycline has a longer half-life than tetracycline so is used more commonly. Resistance has not been detected to tetracycline, doxycycline, or clindamycin.</p><p>Adverse effects are common with the tetracyclines and interfere with adherence. Gastrointestinal discomfort and candidiasis are the most frequent complaints. <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">Doxycycline</a> therapy also poses a risk of esophageal ulceration [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/63\" class=\"abstract_t\">63</a>]. Photosensitivity can occur with doxycycline, which can be concerning for fair-skinned travelers using it as prophylaxis for travel to the tropics.</p><p>Tetracyclines should not be given to pregnant women or children less than eight years old because of the risk of deposition in growing bones and teeth. <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">Clindamycin</a> is the preferred alternative in these groups for treatment; clindamycin should not be used in chemoprophylactic regimens to prevent malaria.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">ARTEMISININ DERIVATIVES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The artemisinins are derived from the leaves of the Chinese sweet wormwood plant, <em>Artemisia annua</em>. They have been used in China for the treatment of malaria for over 2000 years and came to attention outside of China in the 1970s and 1980s. Artemisinin formulations include artemether, arteether, dihydroartemisinin, and <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a>. They are marketed as part of combination therapy throughout the world.</p><p>Artemisinins appear to act by binding iron, breaking down peroxide bridges, leading to the generation of free radicals that damage parasite proteins [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/64\" class=\"abstract_t\">64</a>]. They act rapidly, killing blood stages of all <em>Plasmodium</em> species and reducing the parasite biomass [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/65\" class=\"abstract_t\">65</a>]. Artemisinins have the fastest parasite clearance times of any antimalarial [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/66\" class=\"abstract_t\">66</a>]. Artemisinins are active against gametocytes, the parasite form that is infectious to mosquitoes, and their use has been associated with reduced malaria transmission when they were introduced in Thailand [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/67,68\" class=\"abstract_t\">67,68</a>].</p><p>Intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> is first-line therapy for the treatment of severe malaria. It is superior to <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> for treatment of severe malaria with respect to clearing parasitemia and reducing mortality in both children and adults [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/69,70\" class=\"abstract_t\">69,70</a>]. Intravenous artesunate has been made available in the United States through the Centers for Disease Control and Prevention [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/71\" class=\"abstract_t\">71</a>]. Rectal artesunate is used in remote areas of malaria-endemic countries for stabilizing severely ill patients prior to health facility transport for further management [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/72\" class=\"abstract_t\">72</a>].</p><p>Given the short half-life of artemisinins, intravenous therapy must be followed by a longer-acting agent once the patient is able to tolerate oral medication. If used alone (via the parenteral, rectal, or oral route), <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> must be administered for five to seven days. Treatment for less than five days results in recurrent parasitemia several weeks after therapy due to the very short duration of action rather than to artemisinin resistance.</p><p>Artemisinins are generally well tolerated [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/67,73,74\" class=\"abstract_t\">67,73,74</a>]. Type 1 hypersensitivity to the artemisinin compounds has been reported (incidence 1:3000) [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/75\" class=\"abstract_t\">75</a>]. A large-scale study on the adverse effects of orally administered artemisinins demonstrated transient neurologic abnormalities, including nystagmus and disturbances in balance; these effects resolved without lasting sequelae [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/74\" class=\"abstract_t\">74</a>]. Transient neutropenia has been observed in individuals receiving oral <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> at doses higher than that typically prescribed [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/76\" class=\"abstract_t\">76</a>].</p><p>There have been concerns about the use of artemisinins during the first trimester of pregnancy. Animal studies have suggested that the artemisinin derivatives may be teratogenic during organogenesis [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/77,78\" class=\"abstract_t\">77,78</a>]. A limited number of women in their first trimester have been studied without evidence of adverse events. In observational studies, artemisinins administered in the first trimester have not been associated with adverse pregnancy outcomes [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/79,80\" class=\"abstract_t\">79,80</a>].</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Artemisinin-based combination therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In general, artemisinins should not be used as a single agent to prevent emergence of drug resistance and to avoid the need for prolonged therapy. Artemisinin-based combination therapy (ACT) combines the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. ACTs are typically administered for three days and are often available in fixed-dose tablets.</p><p>Five ACTs are recommended by the World Health Organization for the treatment of uncomplicated malaria: <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a>, artesunate-amodiaquine, artesunate-mefloquine, artesunate-sulfadoxine-pyrimethamine, and dihydroartemisinin-piperaquine [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/46\" class=\"abstract_t\">46</a>]. Artemether-lumefantrine is the most widely adopted ACT in Africa, followed by artesunate-amodiaquine [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/81\" class=\"abstract_t\">81</a>]. Dihydroartemisinin-piperaquine is being widely used in research studies and pilot programs for intermittent treatment and targeted parasite elimination programs.</p><p>Pyronaridine-artesunate is a newer ACT formulation with similar efficacy to <a href=\"topic.htm?path=artemether-and-lumefantrine-drug-information\" class=\"drug drug_general\">artemether-lumefantrine</a> and artesunate-mefloquine for treatment of uncomplicated <em>P. falciparum</em> malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/82-84\" class=\"abstract_t\">82-84</a>]. Pyronaridine is active against chloroquine-resistant infections, although there has been concern about the emergence of resistance if used as monotherapy [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/85,86\" class=\"abstract_t\">85,86</a>]. Pyronaridine-artesunate may cause hepatotoxicity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/87,88\" class=\"abstract_t\">87,88</a>]. Advantages of pyronaridine include its structural dissimilarity to other antimalarial drugs, long shelf-life, and once-daily dosing.</p><p class=\"headingAnchor\" id=\"H1137919195\"><span class=\"h2\">Artemisinin resistance</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reduced susceptibility to artemisinins, as evidenced by delayed parasite clearance time, has been demonstrated in Southeast Asia but not sub-Saharan Africa [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/89-92\" class=\"abstract_t\">89-92</a>]. Point mutations in the kelch protein K13 are associated with this reduced susceptibility [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/91,93-95\" class=\"abstract_t\">91,93-95</a>]; the underlying mechanism is not known. Many of these mutations have arisen independently in Southeast Asia, but resistance has also spread within the region [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/94\" class=\"abstract_t\">94</a>].</p><p>Decreased susceptibility to artemisinins may increase the likelihood of developing resistance to partner drugs. Dihydroartemisinin-piperaquine treatment failures in Cambodia have occurred where artemisinin resistance is emerging [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/96-98\" class=\"abstract_t\">96-98</a>]. The mechanism for piperaquine resistance has not yet been determined; increased copy numbers of <em>plasmepsin 2</em> and <em>plasmepsin 3</em>, two genes that encode proteases that digest hemoglobin, serve as markers for resistance [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/99,100\" class=\"abstract_t\">99,100</a>]. A novel mutation in the <em>pfcrt</em> gene is also associated with decreased piperaquine sensitivity [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/101\" class=\"abstract_t\">101</a>].</p><p>Because the artemisinins are the cornerstone of nearly all new combination therapies, the World Health Organization has called for the banning of all manufacturing and distribution of oral artemisinin monotherapy to deter resistance.</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">INVESTIGATIONAL DRUGS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Agents for treatment of malaria under study or development include KAE609 (a synthetic antimalarial spiroindolone analog) [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/102\" class=\"abstract_t\">102</a>], KAF156 [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/103\" class=\"abstract_t\">103</a>], ferroquine [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/104\" class=\"abstract_t\">104</a>], tafenoquine [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/105\" class=\"abstract_t\">105</a>], malarial protease inhibitors, macrolides [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/106\" class=\"abstract_t\">106</a>], and arterolane [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/107\" class=\"abstract_t\">107</a>].</p><p>KAE609 (cipargamin) targets a parasite plasma membrane Na<sup>+</sup>-ATPase and has been shown to have potent dose-dependent activity against asexual and sexual stage parasites [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/108\" class=\"abstract_t\">108</a>]. In a phase II study in Thailand, three days of treatment (30 mg daily) cleared parasitemia rapidly in 11 adults with uncomplicated <em>P. falciparum</em> malaria and 10 adults with <em>P. vivax</em> malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/102\" class=\"abstract_t\">102</a>].</p><p>KAF156 (an imidazolopiperazine) has activity against blood and preerythrocytic liver parasite stages by an unknown mechanism; antimalarial activity was observed in a small trial of adults with uncomplicated <em>P. vivax</em> or <em>P. falciparum</em> malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/103\" class=\"abstract_t\">103</a>]. The drug has activity against artemisinin-resistant parasites and clears parasites more rapidly than <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">atovaquone-proguanil</a> and <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a> but less rapidly than KAE609. It is being considered as part of a combination treatment regimen.</p><p>Ferroquine, a 4-aminoquinoline, is similar in structure to <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> and has activity against chloroquine-resistant <em>P. falciparum</em>. In a phase II study in sub-Saharan Africa, a three-day course of ferroquine in combination with <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> was effective in treating uncomplicated <em>P. falciparum</em> malaria [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/104\" class=\"abstract_t\">104</a>]. The potential use of ferroquine in combination with other antimalarial drugs in development is being explored.</p><p>Tafenoquine is a long-acting 8-aminoquinoline that, like <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a>, targets <em>P. vivax</em> hypnozoites. A phase IIb trial of adults in Asia and South America found that a single dose of tafenoquine in conjunction with <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> may be more effective at preventing<em> P. vivax</em> relapse than a 14-day course of primaquine with chloroquine [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/105,109\" class=\"abstract_t\">105,109</a>]. As with primaquine, tafenoquine can induce hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.</p><p>Arterolane is a synthetic trioxolane structurally similar to the artemisinins [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/110\" class=\"abstract_t\">110</a>]. In phase III trials among children and adults in Asia and sub-Saharan Africa, a three-day course of arterolane in combination with piperaquine was safe and efficacious for treatment of uncomplicated <em>P. falciparum</em> infection [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/107,111\" class=\"abstract_t\">107,111</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">DRUG QUALITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Counterfeit and low-quality antimalarial medications are significant concerns worldwide, with implications for treatment failure among individual patients and public health concerns related to development of drug resistance. In surveys of antimalarial medications purchased in Southeast Asia, 30 to 50 percent of medications were counterfeit, containing a subtherapeutic or undetectable amount of active ingredient [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/112-114\" class=\"abstract_t\">112-114</a>]. These samples were purchased in a range of different venues, including informal shops, pharmacies, and hospitals. There is increasing evidence of poor quality and counterfeiting of antimalarial drugs in Africa, especially those purchased outside the formal health care system [<a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/115,116\" class=\"abstract_t\">115,116</a>].</p><p class=\"headingAnchor\" id=\"H13746045\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimalarial drugs are used for the treatment and prevention of malaria infection. Most antimalarial drugs target the erythrocytic stage of malaria infection, which is the phase of infection that causes symptomatic illness (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 1</a>). Treatment of the acute blood stage infection is necessary for malaria caused by all malaria species. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of infection due to <em>P. ovale</em> or <em>P. vivax</em>, terminal prophylaxis is also required with a drug active against hypnozoites, which can otherwise remain dormant in the liver for months to years after infection. <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> is the only medication licensed for elimination of hypnozoites. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Quinoline derivatives (<a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a>, amodiaquine, piperaquine, <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a>, <a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">quinidine</a>, <a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">mefloquine</a>, <a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">primaquine</a>, lumefantrine, and halofantrine) have activity against the erythrocytic stage of infection; primaquine also kills intrahepatic forms and gametocytes (<a href=\"image.htm?imageKey=ID%2F79113\" class=\"graphic graphic_figure graphicRef79113 \">figure 1</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Widespread resistance in most malaria-endemic countries has led to decline in use of <a href=\"topic.htm?path=chloroquine-drug-information\" class=\"drug drug_general\">chloroquine</a> for the treatment of <em>P. falciparum</em>, although it remains effective for treatment of <em>P. ovale</em>, <em>P. malariae</em>, and, in most regions, <em>P. vivax</em>. (See <a href=\"#H4\" class=\"local\">'Chloroquine'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">Quinine</a> exists in oral and parenteral forms. In malaria-endemic regions, it is the most commonly used parenteral antimalarial drug, and, in many regions, it is the only available agent for severe malaria, although, in the United States, quinine is only available in its oral form. (See <a href=\"#H7\" class=\"local\">'Quinine and quinidine'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><a href=\"topic.htm?path=mefloquine-drug-information\" class=\"drug drug_general\">Mefloquine</a> is available as an oral formulation and may be used as treatment or prophylaxis for all susceptible malaria species. However, side effects can limit tolerability. (See <a href=\"#H8\" class=\"local\">'Mefloquine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=primaquine-drug-information\" class=\"drug drug_general\">Primaquine</a> is used to prevent relapse of <em>P. ovale</em> and <em>P. vivax </em>malaria by eliminating dormant hypnozoites, and it also has activity against the preerythrocytic stage and gametocytes of <em>P. falciparum</em>. (See <a href=\"#H10\" class=\"local\">'Primaquine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antifolates (sulfonamides, <a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">pyrimethamine</a>, proguanil, and <a href=\"topic.htm?path=dapsone-drug-information\" class=\"drug drug_general\">dapsone</a>) act synergistically to target enzymes involved in folate synthesis, a pathway required for parasite DNA synthesis. <a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a> interferes with two separate pathways involved in the biosynthesis of pyrimidines essential for nucleic acid replication. (See <a href=\"#H12\" class=\"local\">'Antifolates'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a>, <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a>, and <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> target prokaryotic protein synthesis. They are typically paired with fast-acting antimalarials (usually <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a>). (See <a href=\"#H15\" class=\"local\">'Antimicrobials'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous <a href=\"topic.htm?path=artesunate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">artesunate</a> is superior to <a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">quinine</a> for treatment of severe malaria with respect to clearing parasitemia and reducing mortality. Artemisinin-based combination therapy combines the highly effective short-acting artemisinins with a longer-acting partner to protect against artemisinin resistance and to facilitate dosing convenience. (See <a href=\"#H16\" class=\"local\">'Artemisinin derivatives'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/1\" class=\"nounderline abstract_t\">White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/2\" class=\"nounderline abstract_t\">Warhurst DC, Steele JC, Adagu IS, et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J Antimicrob Chemother 2003; 52:188.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/3\" class=\"nounderline abstract_t\">EKPECHI OL, OKORO AN. A PATTERN OF PRURITUS DUE TO CHLOROQUINE. Arch Dermatol 1964; 89:631.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/4\" class=\"nounderline abstract_t\">Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004; 27:25.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/5\" class=\"nounderline abstract_t\">Severe and complicated malaria. World Health Organization Malaria Action Programme. Trans R Soc Trop Med Hyg 1986; 80 Suppl:3.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/6\" class=\"nounderline abstract_t\">SCOTT V. Single intravenous injections of chloroquine in the treatment of falciparum malaria: toxic and immediate therapeutic effects in 110 cases. Am J Trop Med Hyg 1950; 30:503.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/7\" class=\"nounderline abstract_t\">Djimd&eacute; A, Doumbo OK, Cortese JF, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001; 344:257.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/8\" class=\"nounderline abstract_t\">Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6:861.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/9\" class=\"nounderline abstract_t\">Wellems TE, Plowe CV. Chloroquine-resistant malaria. J Infect Dis 2001; 184:770.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/10\" class=\"nounderline abstract_t\">Wootton JC, Feng X, Ferdig MT, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418:320.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/11\" class=\"nounderline abstract_t\">Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27:594.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/12\" class=\"nounderline abstract_t\">Sidhu AB, Verdier-Pinard D, Fidock DA. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002; 298:210.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/13\" class=\"nounderline abstract_t\">Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev 2003; :CD000016.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/14\" class=\"nounderline abstract_t\">Venkatesan M, Gadalla NB, Stepniewska K, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 2014; 91:833.</a></li><li class=\"breakAll\">World Health Organization. WHO List of Prequalified Medicinal Products. http://www.who.int/prequal/query/ProductRegistry.aspx (Accessed on February 13, 2009).</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/16\" class=\"nounderline abstract_t\">Olliaro P, Nevill C, LeBras J, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996; 348:1196.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/17\" class=\"nounderline abstract_t\">Massaga JJ, Lusingu JP, Makunde R, et al. Biological and haematological safety profile of oral amodiaquine and chloroquine in healthy volunteers with or without Plasmodium falciparum infection in northeast Tanzania. Tanzan J Health Res 2008; 10:144.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/18\" class=\"nounderline abstract_t\">Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/19\" class=\"nounderline abstract_t\">Zwang J, Ndiaye JL, Djimd&eacute; A, et al. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J 2012; 11:25.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/20\" class=\"nounderline abstract_t\">Phillips-Howard PA, West LJ. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethamine-dapsone and to amodiaquine in Britain. J R Soc Med 1990; 83:82.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/21\" class=\"nounderline abstract_t\">Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1:411.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/22\" class=\"nounderline abstract_t\">Neftel KA, Woodtly W, Schmid M, et al. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986; 292:721.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/23\" class=\"nounderline abstract_t\">Keating GM. Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs 2012; 72:937.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/24\" class=\"nounderline abstract_t\">Tarning J, Zongo I, Som&eacute; FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012; 91:497.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/25\" class=\"nounderline abstract_t\">Hung TY, Davis TM, Ilett KF, et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol 2004; 57:253.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/26\" class=\"nounderline abstract_t\">Manning J, Vanachayangkul P, Lon C, et al. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 2014; 58:6056.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/27\" class=\"nounderline abstract_t\">Baiden R, Oduro A, Halidou T, et al. Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim&reg; (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. Malar J 2015; 14:160.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/28\" class=\"nounderline abstract_t\">Phillips RE, Warrell DA, White NJ, et al. Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med 1985; 312:1273.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/29\" class=\"nounderline abstract_t\">Pukrittayakamee S, Supanaranond W, Looareesuwan S, et al. Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans R Soc Trop Med Hyg 1994; 88:324.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/30\" class=\"nounderline abstract_t\">Lesi A, Meremikwu M. High first dose quinine regimen for treating severe malaria. Cochrane Database Syst Rev 2004; :CD003341.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/31\" class=\"nounderline abstract_t\">Phillips RE, Looareesuwan S, White NJ, et al. Hypoglycaemia and antimalarial drugs: quinidine and release of insulin. Br Med J (Clin Res Ed) 1986; 292:1319.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/32\" class=\"nounderline abstract_t\">Ferdig MT, Cooper RA, Mu J, et al. Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol 2004; 52:985.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/33\" class=\"nounderline abstract_t\">Deen JL, von Seidlein L, Dondorp A. Therapy of uncomplicated malaria in children: a review of treatment principles, essential drugs and current recommendations. Trop Med Int Health 2008; 13:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/34\" class=\"nounderline abstract_t\">Chen LH, Wilson ME, Schlagenhauf P. Controversies and misconceptions in malaria chemoprophylaxis for travelers. JAMA 2007; 297:2251.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/35\" class=\"nounderline abstract_t\">Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27:203.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/36\" class=\"nounderline abstract_t\">Katsenos S, Psathakis K, Nikolopoulou MI, Constantopoulos SH. Mefloquine-induced eosinophilic pneumonia. Pharmacotherapy 2007; 27:1767.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/37\" class=\"nounderline abstract_t\">Soentjens P, Delanote M, Van Gompel A. Mefloquine-induced pneumonitis. J Travel Med 2006; 13:172.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/38\" class=\"nounderline abstract_t\">Inoue T, Tanaka E, Sakuramoto M, et al. [Case of drug-induced pneumonia possibly due to mefloquine (antimalarial drug)]. Nihon Kokyuki Gakkai Zasshi 2005; 43:103.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/39\" class=\"nounderline abstract_t\">Udry E, Bailly F, Dusmet M, et al. Pulmonary toxicity with mefloquine. Eur Respir J 2001; 18:890.</a></li><li class=\"breakAll\">Food and Drug Administration. Postmarketing Reviews - Volume 1, Number 4, Summer 2008. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm120613.htm (Accessed on September 19, 2008).</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/41\" class=\"nounderline abstract_t\">Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/42\" class=\"nounderline abstract_t\">Rogers WO, Sem R, Tero T, et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia. Malar J 2009; 8:10.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/43\" class=\"nounderline abstract_t\">Chaorattanakawee S, Saunders DL, Sea D, et al. Ex Vivo Drug Susceptibility Testing and Molecular Profiling of Clinical Plasmodium falciparum Isolates from Cambodia from 2008 to 2013 Suggest Emerging Piperaquine Resistance. Antimicrob Agents Chemother 2015; 59:4631.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/44\" class=\"nounderline abstract_t\">Baird JK, Fryauff DJ, Hoffman SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37:1659.</a></li><li class=\"breakAll\">US Food and Drug Administration. Primaquine: Phosphate Tablets, USP. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/008316s021lbl.pdf (Accessed on April 29, 2015).</li><li class=\"breakAll\">World Health Organization. Guidelines for the treatment of malaria, 3rd ed, WHO, Geneva 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/ (Accessed on September 10, 2015).</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/47\" class=\"nounderline abstract_t\">Shekalaghe S, Drakeley C, Gosling R, et al. Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2007; 2:e1023.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/48\" class=\"nounderline abstract_t\">Sutanto I, Suprijanto S, Kosasih A, et al. The effect of primaquine on gametocyte development and clearance in the treatment of uncomplicated falciparum malaria with dihydroartemisinin-piperaquine in South sumatra, Western indonesia: an open-label, randomized, controlled trial. Clin Infect Dis 2013; 56:685.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/49\" class=\"nounderline abstract_t\">Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol Biochem Parasitol 2007; 152:181.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/50\" class=\"nounderline abstract_t\">Miller KD, Lobel HO, Satriale RF, et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35:451.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/51\" class=\"nounderline abstract_t\">Gimnig JE, MacArthur JR, M'bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006; 74:738.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/52\" class=\"nounderline abstract_t\">ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. JAMA 2007; 297:2603.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/53\" class=\"nounderline abstract_t\">Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54:1140.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/54\" class=\"nounderline abstract_t\">Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334.</a></li><li class=\"breakAll\">GlaxoSmithKline. Malarone prescribing information. 2008.</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/56\" class=\"nounderline abstract_t\">Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999; 60:533.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/57\" class=\"nounderline abstract_t\">Happi CT, Gbotosho GO, Folarin OA, et al. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed Plasmodium falciparum isolates from Africa. Malar J 2006; 5:82.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/58\" class=\"nounderline abstract_t\">Schw&ouml;bel B, Alifrangis M, Salanti A, Jelinek T. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2003; 2:5.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/59\" class=\"nounderline abstract_t\">Goodman CD, Siregar JE, Mollard V, et al. Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes. Science 2016; 352:349.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/60\" class=\"nounderline abstract_t\">Nakato H, Vivancos R, Hunter PR. A systematic review and meta-analysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother 2007; 60:929.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/61\" class=\"nounderline abstract_t\">Krudsood S, Patel SN, Tangpukdee N, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2007; 76:655.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/62\" class=\"nounderline abstract_t\">Dahl EL, Shock JL, Shenai BR, et al. Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 2006; 50:3124.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/63\" class=\"nounderline abstract_t\">Al-Mofarreh MA, Al Mofleh IA. Esophageal ulceration complicating doxycycline therapy. World J Gastroenterol 2003; 9:609.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/64\" class=\"nounderline abstract_t\">Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424:957.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/65\" class=\"nounderline abstract_t\">White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41:1413.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/66\" class=\"nounderline abstract_t\">White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88 Suppl 1:S41.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/67\" class=\"nounderline abstract_t\">Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 2004; 363:9.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/68\" class=\"nounderline abstract_t\">Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 2000; 356:297.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/69\" class=\"nounderline abstract_t\">Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/70\" class=\"nounderline abstract_t\">Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.</a></li><li class=\"breakAll\">Center for Disease Control and Prevention. Artesunate now available to treat severe malaria in US. In: Centers for Disease Control and Prevention [electronic mail system]. 2008.</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/72\" class=\"nounderline abstract_t\">Gomes M, Ribeiro I, Warsame M, et al. Rectal artemisinins for malaria: a review of efficacy and safety from individual patient data in clinical studies. BMC Infect Dis 2008; 8:39.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/73\" class=\"nounderline abstract_t\">Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg 2004; 98:73.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/74\" class=\"nounderline abstract_t\">Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999; 60:547.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/75\" class=\"nounderline abstract_t\">Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001; 95:182.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/76\" class=\"nounderline abstract_t\">Bethell D, Se Y, Lon C, et al. Dose-dependent risk of neutropenia after 7-day courses of artesunate monotherapy in Cambodian patients with acute Plasmodium falciparum malaria. Clin Infect Dis 2010; 51:e105.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/77\" class=\"nounderline abstract_t\">Clark RL, Lerman SA, Cox EM, et al. Developmental toxicity of artesunate in the rat: comparison to other artemisinins, comparison of embryotoxicity and kinetics by oral and intravenous routes, and relationship to maternal reticulocyte count. Birth Defects Res B Dev Reprod Toxicol 2008; 83:397.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/78\" class=\"nounderline abstract_t\">Clark RL, Arima A, Makori N, et al. Artesunate: developmental toxicity and toxicokinetics in monkeys. Birth Defects Res B Dev Reprod Toxicol 2008; 83:418.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/79\" class=\"nounderline abstract_t\">Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis 2016; 16:576.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/80\" class=\"nounderline abstract_t\">Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J 2015; 14:461.</a></li><li class=\"breakAll\">World Health Organization. World malaria report 2009. WHO Press, Geneva 2009. http://whqlibdoc.who.int/publications/2009/9789241563901_eng.pdf (Accessed on December 16, 2010).</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/82\" class=\"nounderline abstract_t\">Ramharter M, Kurth F, Schreier AC, et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J Infect Dis 2008; 198:911.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/83\" class=\"nounderline abstract_t\">Tshefu AK, Gaye O, Kayentao K, et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 2010; 375:1457.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/84\" class=\"nounderline abstract_t\">Rueangweerayut R, Phyo AP, Uthaisin C, et al. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. N Engl J Med 2012; 366:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/85\" class=\"nounderline abstract_t\">Ringwald P, Bickii J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26:946.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/86\" class=\"nounderline abstract_t\">Vivas L, Rattray L, Stewart L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop 2008; 105:222.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/87\" class=\"nounderline abstract_t\">Bukirwa H, Unnikrishnan B, Kramer CV, et al. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; :CD006404.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/88\" class=\"nounderline abstract_t\">Sagara I, Beavogui AH, Zongo I, et al. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis 2016; 16:189.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/89\" class=\"nounderline abstract_t\">Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/90\" class=\"nounderline abstract_t\">Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/91\" class=\"nounderline abstract_t\">Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014; 371:411.</a></li><li class=\"breakAll\">World Health Organization. World Malaria Report 2017. http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf?ua=1 (Accessed on January 05, 2018).</li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/93\" class=\"nounderline abstract_t\">Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505:50.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/94\" class=\"nounderline abstract_t\">Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis 2015; 211:670.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/95\" class=\"nounderline abstract_t\">Phyo AP, Ashley EA, Anderson TJ, et al. Declining Efficacy of Artemisinin Combination Therapy Against P. Falciparum Malaria on the Thai-Myanmar Border (2003-2013): The Role of Parasite Genetic Factors. Clin Infect Dis 2016; 63:784.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/96\" class=\"nounderline abstract_t\">Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother 2013; 57:818.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/97\" class=\"nounderline abstract_t\">Saunders DL, Vanachayangkul P, Lon C, et al. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 2014; 371:484.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/98\" class=\"nounderline abstract_t\">Amaratunga C, Lim P, Suon S, et al. Dihydroartemisinin-piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 2016; 16:357.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/99\" class=\"nounderline abstract_t\">Amato R, Pearson RD, Almagro-Garcia J, et al. Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study. Lancet Infect Dis 2018; 18:337.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/100\" class=\"nounderline abstract_t\">Witkowski B, Duru V, Khim N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 2017; 17:174.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/101\" class=\"nounderline abstract_t\">Agrawal S, Moser KA, Morton L, et al. Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity. J Infect Dis 2017; 216:468.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/102\" class=\"nounderline abstract_t\">White NJ, Pukrittayakamee S, Phyo AP, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med 2014; 371:403.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/103\" class=\"nounderline abstract_t\">White NJ, Duong TT, Uthaisin C, et al. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. N Engl J Med 2016; 375:1152.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/104\" class=\"nounderline abstract_t\">Held J, Supan C, Salazar CL, et al. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis 2015; 15:1409.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/105\" class=\"nounderline abstract_t\">Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 2014; 383:1049.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/106\" class=\"nounderline abstract_t\">Rosenthal PJ. Proteases of malaria parasites: new targets for chemotherapy. Emerg Infect Dis 1998; 4:49.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/107\" class=\"nounderline abstract_t\">Toure OA, Valecha N, Tshefu AK, et al. A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa. Clin Infect Dis 2016; 62:964.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/108\" class=\"nounderline abstract_t\">Spillman NJ, Allen RJ, McNamara CW, et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe 2013; 13:227.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/109\" class=\"nounderline abstract_t\">Rajapakse S, Rodrigo C, Fernando SD. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev 2015; :CD010458.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/110\" class=\"nounderline abstract_t\">Vennerstrom JL, Arbe-Barnes S, Brun R, et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430:900.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/111\" class=\"nounderline abstract_t\">Toure OA, Mwapasa V, Sagara I, et al. Assessment of Efficacy and Safety of Arterolane Maleate-Piperaquine Phosphate Dispersible Tablets in Comparison With Artemether-Lumefantrine Dispersible Tablets in Pediatric Patients With Acute Uncomplicated Plasmodium falciparum Malaria: A Phase 3, Randomized, Multicenter Trial in India and Africa. Clin Infect Dis 2017; 65:1711.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/112\" class=\"nounderline abstract_t\">Dondorp AM, Newton PN, Mayxay M, et al. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health 2004; 9:1241.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/113\" class=\"nounderline abstract_t\">Newton P, Proux S, Green M, et al. Fake artesunate in southeast Asia. Lancet 2001; 357:1948.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/114\" class=\"nounderline abstract_t\">Newton PN, Fern&aacute;ndez FM, Plan&ccedil;on A, et al. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 2008; 5:e32.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/115\" class=\"nounderline abstract_t\">Bate R, Coticelli P, Tren R, Attaran A. Antimalarial drug quality in the most severely malarious parts of Africa - a six country study. PLoS One 2008; 3:e2132.</a></li><li><a href=\"https://www.uptodate.com/contents/antimalarial-drugs-an-overview/abstract/116\" class=\"nounderline abstract_t\">Nayyar GM, Breman JG, Newton PN, Herrington J. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 2012; 12:488.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 468 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13746045\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">QUINOLINE DERIVATIVES</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">4-aminoquinolines</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Chloroquine</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">- Amodiaquine</a></li><li><a href=\"#H1659878822\" id=\"outline-link-H1659878822\">- Piperaquine</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">4-methanolquinolines</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Quinine and quinidine</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Mefloquine</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">8-aminoquinolines</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Primaquine</a></li></ul></li></ul></li><li><a href=\"#H12\" id=\"outline-link-H12\">ANTIFOLATES</a><ul><li><a href=\"#H13\" id=\"outline-link-H13\">Sulfadoxine-pyrimethamine</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Atovaquone-proguanil</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">ANTIMICROBIALS</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">ARTEMISININ DERIVATIVES</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">Artemisinin-based combination therapies</a></li><li><a href=\"#H1137919195\" id=\"outline-link-H1137919195\">Artemisinin resistance</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">INVESTIGATIONAL DRUGS</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">DRUG QUALITY</a></li><li><a href=\"#H13746045\" id=\"outline-link-H13746045\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/468|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/79113\" class=\"graphic graphic_figure\">- Malaria life cycle drug targets</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=non-falciparum-malaria-plasmodium-vivax-plasmodium-ovale-and-plasmodium-malariae\" class=\"medical medical_review\">Non-falciparum malaria: Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-malaria-infection-in-travelers\" class=\"medical medical_review\">Prevention of malaria infection in travelers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-severe-malaria\" class=\"medical medical_review\">Treatment of severe malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-uncomplicated-falciparum-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Treatment of uncomplicated falciparum malaria in nonpregnant adults and children</a></li></ul></div></div>","javascript":null}